Multidrug-resistant (MDR) Gram-negative pathogens remain an unmet public health threat.
In recent times, increased rates of resistance have been reported not only to commonly used …

The emergence and spread of multidrug resistant Gram-negative bacteria has led to a
resurgence in the clinical use of polymyxin antibiotics. However, the prevalence of …

Introduction The increasing prevalence of infections with multidrug-resistant (MDR),
extensively-drug resistant (XDR) or difficult-to-treat drug resistant (DTR) Gram-negative …

Due to limited new antibiotics, polymyxins are increasingly used to treat multidrug-resistant
(MDR) Gram-negative bacteria, in particular carbapenem-resistant Acinetobacter …

Infections caused by multi-drug resistant (MDR) bacterial pathogens are a leading cause of
mortality and morbidity across the world. Indiscriminate use of broad-spectrum antibiotics …

Polymyxin B has resurged in recent years as a last resort therapy for Gram‐negative
multidrug‐resistant (MDR) and extremely drug resistant (XDR) infections. Understanding …

Polymyxins have re-emerged in clinical practice owing to the dry antibiotic development
pipeline and worldwide increasing prevalence of nosocomial infections caused by multidrug …

The emergence of antimicrobial resistance of Gram-negative pathogens has become a
worldwide crisis. The status quo for combating resistance is to employ synergistic …

The manuscripts contained in this special edition of Antibiotics represent a current review of
the polymyxins as well as highlights from the 3rd International Polymyxin Conference, which …

Multidrug resistance in pathogens is an increasingly significant threat for human health.
Indeed, some strains are resistant to almost all currently available antibiotics, leaving very …